Myocardial Infarction Risk for Women with Breast Cancer: Annotated Bibliography
Abdel-Qadir, H., Amir, E., Fischer, H. D., Fu, L., Austin, P. C., Harvey, P. J., ... & Anderson, G. M. (2016). The risk of myocardial infarction with aromatase inhibitors relative to tamoxifen in post-menopausal women with early stage breast cancer. European Journal of Cancer, 68, 11-21.
The rationale for this study was that a gap in the literature existed with respect to the possibility of aromatase inhibitors increasing cardiovascular risk relative to tamoxifen among breast cancer patients who were in the post-menopause phase of life. The participants consisted of more 9500 women over the age of 55 suffering from breast cancer (stage 1 to 3) in Ontario, Canada. The researchers conducted an observational cohort study to observe the myocardial infarction risk of aromatase inhibitors and tamoxifen. They examined cases of hospitalization of the population sampled as a result of myocardial infarction and compared cases of those being treated with aromatase inhibitors to those being treated with tamoxifen.
The researchers found that aromatase inhibitors were associated with higher risk of myocardial infarction compared to risk associated with tamoxifen. The implications for clinical practice are that nurses and physicians should consider restricting treatment of breast cancer in post-menopausal women to tamoxifen and not use aromatase inhibitors such as Arimidex, Aromasin or Femara as these can raise the risk of myocardial infarction. Reduction of aromatase inhibitors could help to lower the rate of hospitalization for myocardial infarction for this particular population as well.
Cheng, Y. J., Nie, X. Y., Ji, C. C., Lin, X. X., Liu, L. J., Chen, X. M., ... & Wu, S. H. (2017). Long?Term Cardiovascular Risk After Radiotherapy in Women With Breast Cancer. Journal of the American Heart Association, 6(5), e005633.
The rationale for this study was to obtain quantitative data that...
Jones, L. W., Habel, L. A., Weltzien, E., Castillo, A., Gupta, D., Kroenke, C. H., ... & Yu, A. (2016). Exercise and risk of cardiovascular events in women with nonmetastatic breast cancer. Journal of Clinical Oncology, 34(23), 2743.
James, M., Swadi, S., Yi, M., Johansson, L., Robinson, B., & Dixit, A. (2018). Ischaemic heart disease following conventional and hypofractionated radiation treatment in a contemporary breast cancer series. Journal of medical imaging and radiation oncology.
Abdel-Qadir, H., Amir, E., Fischer, H. D., Fu, L., Austin, P. C., Harvey, P. J., ... & Anderson, G. M. (2016). The risk of myocardial infarction with aromatase inhibitors relative to tamoxifen in post-menopausal women with early stage breast cancer. European Journal of Cancer, 68, 11-21.
Cheng, Y. J., Nie, X. Y., Ji, C. C., Lin, X. X., Liu, L. J., Chen, X. M., ... & Wu, S. H. (2017). Long?Term Cardiovascular Risk After Radiotherapy in Women With Breast Cancer. Journal of the American Heart Association, 6(5), e005633.
Darby, S. C., Ewertz, M., McGale, P., Bennet, A. M., Blom-Goldman, U., Brønnum, D.,... & Jensen, M. B. (2013). Risk of ischemic heart disease in women after radiotherapy for breast cancer. New England Journal of Medicine, 368(11), 987-998.
Our semester plans gives you unlimited, unrestricted access to our entire library of resources —writing tools, guides, example essays, tutorials, class notes, and more.
Get Started Now